Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 25% during trading on Thursday . The stock traded as high as C$0.15 and last traded at C$0.15. Approximately 411,648 shares changed hands during trading, a decline of 11% from the average daily volume of 461,633 shares. The stock had previously closed at C$0.12.
Hemostemix Price Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock’s 50 day moving average price is C$0.10 and its two-hundred day moving average price is C$0.14. The firm has a market capitalization of C$19.67 million, a price-to-earnings ratio of -3.94 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Best Energy Stocks – Energy Stocks to Buy Now
- IBM Up 10 Days in a Row: What’s Driving the Winning Streak?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Upstart Stock’s Bull Case Just Got a Lot Stronger
- Comparing and Trading High PE Ratio Stocks
- Higher Gulf Oil Output Puts These Energy Names in Play
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
